INAB · IN8bio, Inc.

IN8bio reported a narrower GAAP operating loss of -$5.1 million for Q1 FY2026, an 8.3% improvement from -$5.5 million in the prior-year quarter. This reduction reflects the Company's ongoing deployment of cash preservation measures designed to defer or reduce costs in the near term, thereby preserving capital and enhancing financial flexibility during a period of sustained clinical development efforts. These measures align with management's focus on maintaining operational efficiency without halting core research and development activities, which remain the primary use of capital alongside compensation, manufacturing, clinical costs, and regulatory expenses.

Net income mirrored the operating loss at -$5.1 million, also showing an 8.3% year-over-year improvement from the prior period's -$5.5 million. However, diluted EPS worsened significantly to -$0.26 from -$0.07, a -271.4% change, underscoring the per-share impact of the loss amid changes in share structure. This divergence highlights how cost control efforts mitigated the absolute loss magnitude but did not fully offset pressures on per-share metrics.

Looking forward, management anticipates research and development expenses will rise as clinical programs advance and new candidates are developed, driven by the inherently higher costs of later-stage trials due to their increased size and duration. General and administrative expenses are also expected to grow, contingent on securing additional funding to support organizational expansion, headcount increases, and potential commercialization. These dynamics emphasize the critical role of cash preservation in extending financial flexibility while positioning the Company to capitalize on pipeline progress, though sustained funding will be essential to navigate escalating development costs.